Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (SPARTA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01983241|
Recruitment Status : Recruiting
First Posted : November 13, 2013
Last Update Posted : March 13, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Emphysema in Alpha-1 PI Deficiency||Biological: Alpha-1 MP Other: 0.9% Sodium Chloride for Injection, USP||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||339 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency|
|Actual Study Start Date :||November 2013|
|Estimated Primary Completion Date :||June 2026|
|Estimated Study Completion Date :||June 2026|
Experimental: Alpha-1 MP 60 mg/kg
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
Biological: Alpha-1 MP
Other Name: Prolastin-C
Experimental: Alpha-1 MP 120 mg/kg
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
Biological: Alpha-1 MP
Other Name: Prolastin-C
Placebo Comparator: Placebo
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
Other: 0.9% Sodium Chloride for Injection, USP
Other Name: Saline
- Change from Baseline in Whole lung PD15 (15th percentile point) [ Time Frame: Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156 ]Whole lung PD15 measured by CT scan
- Adverse Events (AEs) [ Time Frame: Week -3 through Week 160 ]Monitoring of AEs
- Serious Adverse Events (SAEs) [ Time Frame: Week -3 through Week 160 ]Monitoring of SAEs
- Discontinuations from the study due to AEs [ Time Frame: Week -3 through Week 160 ]Monitoring of discontinuations due to AEs
- Severe COPD Exacerbations [ Time Frame: Week -3 through Week 160 ]Severe COPD exacerbations as defined by American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (i.e., COPD exacerbations requiring hospitalization)
- Change from Baseline in PD15 of the basal lung region [ Time Frame: Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156 ]PD15 of the basal lung region measure by CT scan
- Change from baseline in carbon monoxide diffusing capacity (DLco) [ Time Frame: Weeks 26, 52, 78, 104, 130 and 156 ]DLco performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines
- Changes from baseline in forced expiratory volume in 1 second (FEV1) [ Time Frame: Weeks 26, 52, 78, 104, 130 and 156 ]FEV1 performed according to ATS/ERS guidelines
- Change from baseline in Saint George's Respiratory Questionnaire: Minimum value = 0, maximum value = 100, higher scores indicate worse condition [ Time Frame: Weeks 26, 52, 78, 104, 130 and 156 ]Health-related quality of life assessment tool
- Change from baseline in the EuroQoL (Quality of Life)- 5 Dimension- 5 Level (EQ-5D-5L): Minimum value (for each one of the 5 levels) = 1, maximum value (for each one of the 5 levels) = 5, higher scores indicate worse condition [ Time Frame: Weeks 26, 52, 78, 104, 130 and 156 ]Heath-related quality of life assessment tool
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Have a documented total alpha1-PI serum level < 11 µM.
- Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles.
- At the Screening (Week -3) Visit, have a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30% and < 80% of predicted and FEV1/forced vital capacity (FVC) < 70% (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II or III).
- Have a carbon monoxide diffusing capacity (DLCO) ≤ 60% of predicted (corrected for HgB) within the past 2 years OR evidence of pulmonary emphysema on CT scan within the past 2 years per the Investigator's judgment.
- Have clinical evidence of pulmonary emphysema per the Investigator's judgment.
- Has received alpha1-PI augmentation therapy for more than 1 month within the six months prior to the Screening Visit.
- Has received alpha1-PI augmentation therapy within one month of the Screening Visit.
- Has had a chronic obstructive pulmonary disease (COPD) exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
- Unable to physically (e.g., unable to fit inside the CT scanner) or mentally (e.g., claustrophobic) undergo a CT scan.
- History of lung or liver transplant.
- Any lung surgery during the past 2 years (excluding lung biopsy).
- On the waiting list for lung surgery, including lung transplant.
- Smoking during the past 12 months or a positive urine cotinine test at screening that is due to smoking. Maybe on Nicotine replacement, including vapor cigarettes.
- History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
- Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 5 weeks prior to the Screening Visit (inhaled steroids are not considered systemic steroids) or during the Screening Phase.
- Use of systemic or aerosolized antibiotics for a COPD exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
- Known selective or severe Immunoglobulin A (IgA) deficiency.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01983241
|Contact: David Taylorfirstname.lastname@example.org|
|Contact: Gordon McAlesteremail@example.com|
|Responsible Party:||Grifols Therapeutics LLC|
|Other Study ID Numbers:||
|First Posted:||November 13, 2013 Key Record Dates|
|Last Update Posted:||March 13, 2023|
|Last Verified:||March 2023|
Alpha-1 Antitrypsin Deficiency
Alpha-1 PI Deficiency
Alpha-1 Proteinase Inhibitor
Alpha 1-Antitrypsin Deficiency
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Digestive System Diseases
Genetic Diseases, Inborn
Serine Proteinase Inhibitors
Molecular Mechanisms of Pharmacological Action